Related Experiment Video

Updated: Sep 24, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

566

Approved anti-PD-1 monoclonal antibodies in China: A bridge too far for US approval

Mark P Lythgoe1, Richard Sullivan2

  • 1Department of Surgery and Cancer, Imperial College London, London, United Kingdom.

European Journal of Cancer (Oxford, England : 1990)
|May 9, 2022
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.4K

Related Experiment Videos

Last Updated: Sep 24, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

566
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K

Articles linked to this work by shared authors, journal, and citation graph.

Systematic review of the Lancet Commission on Global Surgery indicators with quality assessment of modelled estimates.

The British journal of surgery·2026

Disparity in the Markers of Affordability Across Targeted- and Immune-Therapy Drugs Used in Head and Neck Cancers.

Head & neck·2026

Feasibility Trial of Prolonged versus Single-Dose Challenge in Penicillin Allergy.

NEJM evidence·2026

Cancer Control in Refugee and Asylum Seeker Populations: A Scoping Review.

JCO global oncology·2026

Accelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines Forum.

Journal of cancer policy·2026

Prioritizing human-centered cancer care in a digital era.

EClinicalMedicine·2026

Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer.

European journal of cancer (Oxford, England : 1990)·2026

Clinically actionable genetic findings by exome sequencing performed for therapeutic purposes in children with very-high risk cancer included the MAPPYACTS study.

European journal of cancer (Oxford, England : 1990)·2026

Single-item measures of perceived side effect burden for people with cancer: A systematic scoping review.

European journal of cancer (Oxford, England : 1990)·2026

Refining neoplasm risk in DICER1-related tumor predisposition.

European journal of cancer (Oxford, England : 1990)·2026

Towards a more proportionate EU framework for low-intervention clinical trials: Lessons from the UK and Switzerland.

European journal of cancer (Oxford, England : 1990)·2026

Recent trends in childhood, teenage and young adult cancer incidence in England (2001-2020).

European journal of cancer (Oxford, England : 1990)·2026

Disproportionality analysis of adverse event signals associated with seven Alzheimer's drugs: insights from the FAERS database.

Frontiers in pharmacology·2026

Ruzinurad: First Approval.

Drugs·2026

The ratio of propylene glycol to glycerol modulates nicotine taste and reward: more glycerol, more reward.

Frontiers in pharmacology·2026

One blotter stamp: Identification of multiple phenethylamine new psychoactive substances and unambiguous differentiation of two isomers.

Journal of forensic sciences·2026

Pharmaceutical quality of artemether-lumefantrine in Rwanda's public health supply chain: a cross-sectional post-market surveillance study.

Malaria journal·2026

Declines in stimulant-involved overdose mortality occurred only with fentanyl co-involvement, United States, 2023-2024.

Drug and alcohol dependence·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us